Benoit H Mulsant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2539867/publications.pdf

Version: 2024-02-01

534 papers 25,842 citations

7069 78 h-index 136 g-index

540 all docs 540 docs citations

540 times ranked

21622 citing authors

#	Article	IF	Citations
1	Association between psychomotor disturbance and treatment outcome in psychotic depression: a STOP-PD II report. Psychological Medicine, 2022, 52, 3957-3963.	2.7	2
2	Diagnostic Precision in the Detection of Mild Cognitive Impairment: A Comparison of Two Approaches. American Journal of Geriatric Psychiatry, 2022, 30, 54-64.	0.6	12
3	Bipolar symptoms, somatic burden, and functioning in olderâ€age bipolar disorder: Analyses from the Global Aging & Geriatric Experiments in Bipolar Disorder Database project. Bipolar Disorders, 2022, 24, 195-206.	1.1	24
4	Increased sympathetic tone is associated with illness burden in bipolar disorder. Journal of Affective Disorders, 2022, 297, 471-476.	2.0	4
5	Metabolic function in patients with bipolar depression receiving anti-inflammatory agents: Findings from the MINDCARE study, a multicentre, randomised controlled trial. Journal of Affective Disorders, 2022, 299, 135-141.	2.0	3
6	The Effect of Repetitive Transcranial Magnetic Stimulation on Suicidal Ideation in Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2022, 83, .	1.1	7
7	Cognitive-Behavioral Social Skills Training for patients with late-life schizophrenia and the moderating effect of executive dysfunction. Schizophrenia Research, 2022, 239, 160-167.	1.1	5
8	Differential Placebo Responses for Pharmacotherapy and Neurostimulation in Late-Life Depression. Neuromodulation, 2022, , .	0.4	0
9	Time setting errors in the Clock Drawing Test are associated with both semantic and executive deficits. Applied Neuropsychology Adult, 2022, , 1-10.	0.7	3
10	Technologyâ€enabled collaborative care for youth with early psychosis: Results of a feasibility study to improve physical health behaviours. Microbial Biotechnology, 2022, 16, 1143-1151.	0.9	6
11	Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia. Schizophrenia Research, 2022, 241, 113-115.	1.1	1
12	Effect of high frequency versus thetaâ€burst repetitive transcranial magnetic stimulation on suicidality in patients with treatmentâ€resistant depression. Acta Psychiatrica Scandinavica, 2022, 145, 529-538.	2.2	6
13	Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial. American Journal of Geriatric Psychiatry, 2022, 30, 994-1002.	0.6	2
14	Optimizing Outcomes of Treatment-Resistant Depression (TRD) in Older Adults (OPTIMUM): Measures of Psychological Well-Being. American Journal of Geriatric Psychiatry, 2022, 30, S111-S112.	0.6	0
15	Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?. Expert Opinion on Drug Safety, 2022, , 1-4.	1.0	2
16	Prevalence of mental health outcomes and effects of sex and mood or cognitive comorbidity in older adults during the COVID-19 pandemic. American Journal of Geriatric Psychiatry, 2022, 30, S115-S116.	0.6	1
17	PAS-MCI: Design and Rationale for a Randomized Controlled Trial to Enhance Prefrontal Cortical Plasticity and Working Memory in Individuals with Amnestic Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2022, 30, S53.	0.6	0
18	"What else can we do?â€â€"Provider perspectives on treatmentâ€resistant depression in late life. Journal of the American Geriatrics Society, 2022, 70, 1190-1197.	1.3	4

#	Article	IF	CITATIONS
19	Physical Health Burden Among Older Men and Women With Bipolar Disorder: Results From the Gage-Bd Collaboration. American Journal of Geriatric Psychiatry, 2022, 30, 727-732.	0.6	14
20	Symptom Severity Mixity in Older-Age Bipolar Disorder: Analyses From the Global Aging and Geriatric Experiments in Bipolar Disorder Database (GAGE-BD). American Journal of Geriatric Psychiatry, 2022, 30, 1096-1107.	0.6	8
21	Identifying patient-specific behaviors to understand illness trajectories and predict relapses in bipolar disorder using passive sensing and deep anomaly detection: protocol for a contactless cohort study. BMC Psychiatry, 2022, 22, 288.	1.1	4
22	Reappraising the variability of effects of antipsychotic medication in schizophrenia: a metaâ€analysis. World Psychiatry, 2022, 21, 287-294.	4.8	26
23	Impact of standardizing care for agitation in dementia using an integrated care pathway on an inpatient geriatric psychiatry unit. International Psychogeriatrics, 2022, 34, 919-928.	0.6	3
24	Factor analysis of the CORE measure of psychomotor disturbance in psychotic depression: Findings from the STOP-PD II study. Psychiatry Research, 2022, 314, 114648.	1.7	3
25	Multiscale neural signatures of major depressive, anxiety, and stress-related disorders. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	5
26	Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome. JAMA Network Open, 2022, 5, e2219678.	2.8	8
27	<scp>Technologyâ€enabled</scp> collaborative care for youth with early psychosis: A protocol for a feasibility study to improve physical health behaviours. Microbial Biotechnology, 2021, 15, 828-836.	0.9	10
28	Magnetic Seizure Therapy for the Treatment of Suicidality in Bipolar Depression. Biological Psychiatry, 2021, 90, e51-e53.	0.7	4
29	Relationships Among History of Psychosis, Cognition and Functioning in Later-Life Remitted Major Depression. American Journal of Geriatric Psychiatry, 2021, 29, 144-155.	0.6	3
30	A doubleâ€blind, randomized, placeboâ€controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users. Bipolar Disorders, 2021, 23, 66-75.	1.1	7
31	Effects of Repetitive Transcranial Magnetic Stimulation on Working Memory Performance and Brain Structure in People With Schizophrenia Spectrum Disorders: A Double-Blind, Randomized, Sham-Controlled Trial. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 449-458.	1.1	5
32	Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia. Journal of Psychopharmacology, 2021, 35, 31-39.	2.0	5
33	A pilot study of magnetic seizure therapy for treatmentâ€resistant obsessive–compulsive disorder. Depression and Anxiety, 2021, 38, 161-171.	2.0	3
34	Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression. Journal of Clinical Psychopharmacology, 2021, 41, 31-35.	0.7	7
35	Predictors of change in suicidal ideation across treatment phases of major depressive disorder: analysis of the STAR*D data. Neuropsychopharmacology, 2021, 46, 1293-1299.	2.8	12
36	Relationship of Hair Cortisol with History of Psychosis, Neuropsychological Performance and Functioning in Remitted Later-Life Major Depression. Neuropsychobiology, 2021, 80, 313-320.	0.9	3

#	Article	IF	CITATIONS
37	The use of sequential pharmacotherapy for the treatment of acute major depression: a scoping review. Expert Opinion on Pharmacotherapy, 2021, 22, 1005-1014.	0.9	1
38	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Translational Psychiatry, 2021, 11, 127.	2.4	22
39	Cortical inhibition, facilitation and plasticity in late-life depression: effects of venlafaxine pharmacotherapy. Journal of Psychiatry and Neuroscience, 2021, 46, E88-E96.	1.4	7
40	Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy. Journal of Clinical Psychopharmacology, 2021, 41, 196-199.	0.7	5
41	Relationships Between a New Cultured Cell-Based Serum Anticholinergic Activity Assay and Anticholinergic Burden Scales or Cognitive Performance in Older Adults. American Journal of Geriatric Psychiatry, 2021, 29, 1239-1252.	0.6	3
42	Comparing cardiovascular risk factors in older persons with mild cognitive impairment and lifetime history of major depressive disorder. International Psychogeriatrics, 2021, , 1-7.	0.6	2
43	The Impact of COVID-19 on Psychiatric Emergency and Inpatient Services in the First Month of the Pandemic in a Large Urban Mental Health Hospital in Ontario, Canada. Frontiers in Psychiatry, 2021, 12, 563906.	1.3	15
44	Optimizing Outcomes of Treatment - Resistant Depression in Older Adults (OPTIMUM): Study Design and Sample. American Journal of Geriatric Psychiatry, 2021, 29, S33-S34.	0.6	3
45	The primary care assessment and research of a telephone intervention for neuropsychiatric conditions with education and resources study: Design, rationale, and sample of the PARTNERs randomized controlled trial. Contemporary Clinical Trials, 2021, 103, 106284.	0.8	3
46	Enhancing Cognition in Older Persons: A Pilot Clinical Trial of Mindfulness-Based Stress Reduction (MBSR) and transcranial Direct Current Stimulation (tDCS). American Journal of Geriatric Psychiatry, 2021, 29, S105-S106.	0.6	0
47	Individual Differences in Response to Antidepressants. JAMA Psychiatry, 2021, 78, 490.	6.0	26
48	Resting State Functional Connectivity and Relapse in Psychotic Depression. Biological Psychiatry, 2021, 89, S96-S97.	0.7	0
49	Reduced heart rate variability is associated with higher illness burden in bipolar disorder. Journal of Psychosomatic Research, 2021, 145, 110478.	1.2	19
50	Placebo response in treatment resistant depression: a systematic review and meta-analysis of multiple treatment modalities. BJPsych Open, 2021, 7, S261-S262.	0.3	0
51	Suicidality in patients with bipolar depression: Findings from a lower middle-income country. Journal of Affective Disorders, 2021, 289, 1-6.	2.0	8
52	An update on antidepressant pharmacotherapy in late-life depression. Expert Opinion on Pharmacotherapy, 2021, 22, 1909-1917.	0.9	8
53	Impact of COVID-19 on motor vehicle injuries and fatalities in older adults in Ontario, Canada. Accident Analysis and Prevention, 2021, 157, 106195.	3.0	20
54	Transcranial magnetic stimulation indices of cortical excitability enhance the prediction of response to pharmacotherapy in late-life depression. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, , .	1.1	1

#	Article	IF	CITATIONS
55	Evolutionary theory and the treatment of depression: It is all about the squids and the sea bass. Behaviour Research and Therapy, 2021, 143, 103849.	1.6	9
56	Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence. Life, 2021, 11, 819.	1.1	10
57	Relationship between childhood trauma, personality, social support and depression in women attending general medical clinics in a low and middle-income country. Journal of Affective Disorders, 2021, 292, 526-533.	2.0	13
58	Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults. JAMA Network Open, 2021, 4, e2125531.	2.8	49
59	The futility of long-term predictions in bipolar disorder: mood fluctuations are the result of deterministic chaotic processes. International Journal of Bipolar Disorders, 2021, 9, 30.	0.8	4
60	Dorsolateral prefrontal cortex excitability abnormalities in Alzheimer's Dementia: Findings from transcranial magnetic stimulation and electroencephalography study. International Journal of Psychophysiology, 2021, 169, 55-62.	0.5	16
61	Antidepressant treatment outcomes in patients with and without comorbid physical or psychiatric disorders: A systematic review and meta-analysis. Journal of Affective Disorders, 2021, 295, 225-234.	2.0	9
62	Apps and gaps in bipolar disorder: A systematic review on electronic monitoring for episode prediction. Journal of Affective Disorders, 2021, 295, 1190-1200.	2.0	11
63	Using Rapid Design Thinking to Overcome COVID-19 Challenges in Medical Education. Academic Medicine, 2021, 96, 56-61.	0.8	56
64	Continuation Magnetic Seizure Therapy for Treatment-Resistant Unipolar or Bipolar Depression. Journal of Clinical Psychiatry, 2021, 82, .	1.1	4
65	Coordinate-Based Network Mapping of Brain Structure in Major Depressive Disorder in Younger and Older Adults: A Systematic Review and Meta-Analysis. American Journal of Psychiatry, 2021, 178, 1119-1128.	4.0	30
66	Enhancing Cognition in Older Persons with Depression or Anxiety with a Combination of Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS): Results of a Pilot Randomized Clinical Trial. Mindfulness, 2021, 12, 1-13.	1.6	17
67	From challenge to opportunity: COVID-19 and the evolution of virtual mental health care Families, Systems and Health, 2021, 39, 659-661.	0.4	6
68	Magnetic seizure therapy (MST) for major depressive disorder. Neuropsychopharmacology, 2020, 45, 276-282.	2.8	50
69	The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. Journal of Affective Disorders, 2020, 262, 149-154.	2.0	14
70	Economic Burden of Depression and Associated Resource Use in Manitoba, Canada. Canadian Journal of Psychiatry, 2020, 65, 338-346.	0.9	32
71	Mood Disorders and Dementia: Time for Action. American Journal of Geriatric Psychiatry, 2020, 28, 542-544.	0.6	0
72	Why Do Older Adults Taking Antidepressants Fall?. American Journal of Geriatric Psychiatry, 2020, 28, 285-287.	0.6	4

#	Article	IF	Citations
73	Effectively Caring for Individuals With Behavioral and Psychological Symptoms of Dementia During the COVID-19 Pandemic. Frontiers in Psychiatry, 2020, 11, 573367.	1.3	51
74	Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study. American Journal of Geriatric Psychiatry, 2020, 29, 645-654.	0.6	2
75	Theta–gamma coupling and ordering information: a stable brain–behavior relationship across cognitive tasks and clinical conditions. Neuropsychopharmacology, 2020, 45, 2038-2047.	2.8	19
76	Article Commentary: COVID-19 and Persons with Substance use Disorders: Inequities and Mitigation Strategies. Substance Abuse, 2020, 41, 286-291.	1.1	95
77	Coping, fostering resilience, and driving care innovation for autistic people and their families during the COVID-19 pandemic and beyond. Molecular Autism, 2020, 11, 61.	2.6	144
78	DIAGNOSING COGNITIVE DECLINE: COMPARING NIA-AA TO DSM-5 APPROACHES. American Journal of Geriatric Psychiatry, 2020, 28, S79-S80.	0.6	2
79	Magnetic Seizure Therapy for Suicidality in Treatment-Resistant Depression. JAMA Network Open, 2020, 3, e207434.	2.8	13
80	Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults. Journal of Psychopharmacology, 2020, 34, 1112-1118.	2.0	5
81	Trial failures of anti-inflammatory drugs in depression – Authors' reply. Lancet Psychiatry,the, 2020, 7, 837-838.	3.7	5
82	Brain Volume Changes Under Treatment With Antipsychotics—Reply. JAMA Psychiatry, 2020, 77, 877.	6.0	2
83	The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults. Journal of Clinical Psychopharmacology, 2020, 40, 553-559.	0.7	7
84	Frontal-executive and corticolimbic structural brain circuitry in older people with remitted depression, mild cognitive impairment, Alzheimer's dementia, and normal cognition. Neuropsychopharmacology, 2020, 45, 1567-1578.	2.8	14
85	Plus ÃSa change? Benzodiazepine prescription in older patients with schizophrenia is common but best avoided. International Psychogeriatrics, 2020, 32, 419-422.	0.6	0
86	Assessing adjunctive treatments for bipolar depression. Lancet Psychiatry, the, 2020, 7, 478-479.	3.7	1
87	The benefits and costs of changing treatment technique in electroconvulsive therapy due to insufficient improvement of a major depressive episode. Brain Stimulation, 2020, 13, 1284-1295.	0.7	12
88	Inflammation as a treatment target in mood disorders: review. BJPsych Open, 2020, 6, e60.	0.3	54
89	Effects of bilateral transcranial direct current stimulation on working memory and global cognition in older patients with remitted major depression: A pilot randomized clinical trial. International Journal of Geriatric Psychiatry, 2020, 35, 1233-1242.	1.3	7
90	Experiences of American Older Adults with Pre-existing Depression During the Beginnings of the COVID-19 Pandemic: A Multicity, Mixed-Methods Study. American Journal of Geriatric Psychiatry, 2020, 28, 924-932.	0.6	108

#	Article	IF	CITATIONS
91	Physician-based availability of psychotherapy in Ontario: a population-based retrospective cohort study. CMAJ Open, 2020, 8, E105-E115.	1.1	12
92	Action at a Distance: Geriatric Research during a Pandemic. Journal of the American Geriatrics Society, 2020, 68, 922-925.	1.3	91
93	Structural brain networks in remitted psychotic depression. Neuropsychopharmacology, 2020, 45, 1223-1231.	2.8	17
94	Design and Rationale of the PACt-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression. Journal of Alzheimer's Disease, 2020, 76, 733-751.	1,2	27
95	Physical health among people with serious mental illness in the face of COVID-19: Concerns and mitigation strategies. General Hospital Psychiatry, 2020, 66, 30-33.	1.2	46
96	Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features. JAMA Psychiatry, 2020, 77, 674.	6.0	76
97	Feasibility of remotely supervised transcranial direct current stimulation and cognitive remediation: A systematic review. PLoS ONE, 2020, 15, e0223029.	1.1	28
98	Individual Differences in Response to Antidepressants. JAMA Psychiatry, 2020, 77, 607.	6.0	36
99	Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 100, 109867.	2.5	8
100	Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. American Journal of Geriatric Psychiatry, 2020, 28, 609-629.	0.6	18
101	The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. Schizophrenia Bulletin, 2020, 46, 752-757.	2.3	277
102	Functional Competence and Cognition in Individuals With Amnestic Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2020, 68, 1787-1795.	1.3	2
103	Anticipating and Mitigating the Impact of the COVID-19 Pandemic on Alzheimer's Disease and Related Dementias. American Journal of Geriatric Psychiatry, 2020, 28, 712-721.	0.6	374
104	Sahaj Samadhi Meditation versus a Health Enhancement Program for depression in chronic pain: protocol for a randomized controlled trial and implementation evaluation. Trials, 2020, 21, 319.	0.7	1
105	Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry,the, 2020, 7, 515-527.	3.7	110
106	COVID-19: Implications for bipolar disorder clinical care and research. SAGE Open Medicine, 2020, 8, 205031212098117.	0.7	12
107	Magnetic seizure therapy is efficacious and well tolerated for treatment-resistant bipolar depression: an open-label clinical trial. Journal of Psychiatry and Neuroscience, 2020, 45, 313-321.	1.4	5
108	Why Do Some Older Adults Treated With Antidepressants Progress to Dementia?. Journal of Clinical Psychiatry, 2020, 81, .	1.1	5

#	Article	IF	CITATIONS
109	Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders. Journal of Clinical Psychiatry, 2020, 81, .	1.1	5
110	THE NATURE OF DEPRESSIVE RUMINATION AND ITS CONNECTION WITH DEPRESSIVE SYMPTOMS. Journal of Social and Clinical Psychology, 2020, 39, 761-787.	0.2	1
111	Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission. JAMA - Journal of the American Medical Association, 2019, 322, 622.	3.8	53
112	Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment. Journal of Neuroimaging, 2019, 29, 721-729.	1.0	6
113	Management of Late-Life Depression in the Context of Cognitive Impairment: a Review of the Recent Literature. Current Psychiatry Reports, 2019, 21, 74.	2.1	21
114	Comorbid anxiety in lateâ€life depression: Relationship with remission and suicidal ideation on venlafaxine treatment. Depression and Anxiety, 2019, 36, 1125-1134.	2.0	31
115	EXAMINING THE IMPACT OF CARDIOVASCULAR RISK FACTORS ON NEUROPSYCHIATRIC SYMPTOMS IN THE PACT-MD STUDY. American Journal of Geriatric Psychiatry, 2019, 27, S202-S203.	0.6	1
116	GENOME-WIDE ANALYSES OF REMISSION ON VENLAFAXINE TREATMENT IN OLDER ADULTS WITH LATE-LIFE DEPRESSION. European Neuropsychopharmacology, 2019, 29, S1045-S1046.	0.3	0
117	Clinical, Demographic, and Criminal Behavior Characteristics of Patients With Intellectual Disabilities in a Canadian Forensic Program. Frontiers in Psychiatry, 2019, 10, 760.	1.3	17
118	178. Brain Network Biomarkers of Remitted Psychotic Depression. Biological Psychiatry, 2019, 85, S73-S74.	0.7	0
119	Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression. Neurolmage: Clinical, 2019, 21, 101679.	1.4	11
120	Challenges in conducting research on collaborative mental health care: a qualitative study. CMAJ Open, 2019, 7, E405-E414.	1.1	9
121	Health-related quality of life in remitted psychotic depression✰. Journal of Affective Disorders, 2019, 256, 373-379.	2.0	3
122	An inverse relationship between cortical plasticity and cognitive inhibition in late-life depression. Neuropsychopharmacology, 2019, 44, 1659-1666.	2.8	9
123	Association between Sleep Disturbances and Medial Temporal Lobe Volume in Older Adults with Mild Cognitive Impairment Free of Lifetime History of Depression. Journal of Alzheimer's Disease, 2019, 69, 413-421.	1.2	11
124	The Global Aging & Ceriatric Experiments in Bipolar Disorder Database (GAGEâ€BD) project: Understanding olderâ€age bipolar disorder by combining multiple datasets. Bipolar Disorders, 2019, 21, 642-649.	1.1	27
125	Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized. American Journal of Geriatric Psychiatry, 2019, 27, 1138-1152.	0.6	40
126	THE ASSOCIATIONS AMONG HISTORY OF PSYCHOSIS, NEUROPSYCHOLOGICAL PERFORMANCE, AND FUNCTIONING IN REMITTED LATER-LIFE MAJOR DEPRESSION. American Journal of Geriatric Psychiatry, 2019, 27, S117-S118.	0.6	0

#	Article	IF	Citations
127	Changes in Theta but not Alpha Modulation Are Associated with Impairment in Working Memory in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 68, 1085-1094.	1.2	16
128	Unilateral and bilateral repetitive transcranial magnetic stimulation for treatmentâ€resistant lateâ€life depression. International Journal of Geriatric Psychiatry, 2019, 34, 822-827.	1.3	35
129	CARDIOVASCULAR BURDEN AND COGNITION IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT AND MAJOR DEPRESSIVE DISORDER. American Journal of Geriatric Psychiatry, 2019, 27, S132-S133.	0.6	1
130	Examining the Link Between Cardiovascular Risk Factors and Neuropsychiatric Symptoms in Mild Cognitive Impairment and Major Depressive Disorder in Remission. Journal of Alzheimer's Disease, 2019, 67, 1305-1311.	1.2	9
131	GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. Focus (American Psychiatric Publishing), 2019, 17, 314-321.	0.4	0
132	124. Separable and Replicable Neural Strategies During Social Brain Function in People With and Without Severe Mental Illness. Biological Psychiatry, 2019, 85, S51-S52.	0.7	0
133	Assessment and treatment of major depression in older adults. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 429-435.	1.0	47
134	Separable and Replicable Neural Strategies During Social Brain Function in People With and Without Severe Mental Illness. American Journal of Psychiatry, 2019, 176, 521-530.	4.0	30
135	Brain structure, cognition, and brain age in schizophrenia, bipolar disorder, and healthy controls. Neuropsychopharmacology, 2019, 44, 898-906.	2.8	107
136	Gender Differences in Research Productivity among Academic Psychiatrists in Canada. Canadian Journal of Psychiatry, 2019, 64, 415-422.	0.9	18
137	Predicting Remission in Late-Life Major Depression. Journal of Clinical Psychiatry, 2019, 80, .	1.1	21
138	Reply. Psychotherapy and Psychosomatics, 2018, 87, 180-180.	4.0	0
139	Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia. Journal of Psychopharmacology, 2018, 32, 509-523.	2.0	79
140	Can Collaborative Care Cure the Mediocrity of Usual Care for Common Mental Disorders?. Canadian Journal of Psychiatry, 2018, 63, 427-431.	0.9	14
141	Impact of brief education on healthy seniors' attitudes and healthcare choices about Alzheimer's disease and associated symptoms. International Psychogeriatrics, 2018, 30, 1889-1897.	0.6	1
142	Continuation Treatment of Remitted Psychotic Depression: The STOP-PD Study. American Journal of Geriatric Psychiatry, 2018, 26, S86-S87.	0.6	0
143	Assessing bipolar disorder in the older adult: the GERIâ€BD toolbox. International Journal of Geriatric Psychiatry, 2018, 33, e150-e157.	1.3	3
144	Electroconvulsive therapy for depression with comorbid borderline personality disorder or post-traumatic stress disorder: A matched retrospective cohort study. Brain Stimulation, 2018, 11, 204-212.	0.7	29

#	Article	IF	CITATIONS
145	Specific depressive symptoms predict remission to aripiprazole augmentation in lateâ€life treatment resistant depression. International Journal of Geriatric Psychiatry, 2018, 33, e330-e335.	1.3	6
146	A Systematic Review of the Measurement of Function in Late-Life Depression. American Journal of Geriatric Psychiatry, 2018, 26, 54-72.	0.6	12
147	Impact of Physician Follow-Up Care on Psychiatric Readmission Rates in a Population-Based Sample of Patients With Schizophrenia. Psychiatric Services, 2018, 69, 61-68.	1.1	30
148	Allostatic load but not medical burden predicts memory performance in lateâ€ife bipolar disorder. International Journal of Geriatric Psychiatry, 2018, 33, 546-552.	1.3	10
149	Brain-Behavior Participant Similarity Networks Among Youth and Emerging Adults with Schizophrenia Spectrum, Autism Spectrum, or Bipolar Disorder and Matched Controls. Neuropsychopharmacology, 2018, 43, 1180-1188.	2.8	45
150	Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. International Journal of Geriatric Psychiatry, 2018, 33, 523-530.	1.3	11
151	The role of late life depressive symptoms on the trajectories of insomnia symptoms during antidepressant treatment. Journal of Psychiatric Research, 2018, 96, 162-166.	1.5	4
152	Mental and physical comorbidity in an Arab primary health care setting. BMC Psychiatry, 2018, 18, 313.	1.1	13
153	Magnetic seizure therapy reduces suicidal ideation and produces neuroplasticity in treatment-resistant depression. Translational Psychiatry, 2018, 8, 253.	2.4	49
154	Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life. Pharmacogenomics, 2018, 19, 1269-1284.	0.6	16
155	Resting state functional connectivity in patients with remitted psychotic depression: A multi-centre STOP-PD study. EBioMedicine, 2018, 36, 446-453.	2.7	10
156	Using sedatives–hypnotics or opioids in older adults: a narrow path. International Psychogeriatrics, 2018, 30, 925-927.	0.6	0
157	Assessment of neuroplasticity in late-life depression with transcranial magnetic stimulation. Journal of Psychiatric Research, 2018, 105, 63-70.	1.5	6
158	Reduced GABAergic cortical inhibition in aging and depression. Neuropsychopharmacology, 2018, 43, 2277-2284.	2.8	34
159	Characteristics of ictal EEG in Magnetic Seizure Therapy at various stimulation frequencies. Clinical Neurophysiology, 2018, 129, 1770-1779.	0.7	14
160	Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial. Neuropsychopharmacology, 2018, 43, 2231-2238.	2.8	104
161	Theta-Gamma Coupling and Working Memory in Alzheimer's Dementia and Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 101.	1.7	103
162	Therapeutic Strategies in Depression with Cognitive Impairment. American Journal of Geriatric Psychiatry, 2018, 26, S18-S20.	0.6	0

#	Article	IF	Citations
163	Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial. BMC Psychiatry, 2018, 18, 227.	1.1	8
164	Statins and cognition in lateâ€life bipolar disorder. International Journal of Geriatric Psychiatry, 2018, 33, 1355-1360.	1.3	6
165	Computer-Aided Telephone Support for Primary Care Patients with Common Mental Health Conditions: Randomized Controlled Trial. JMIR Mental Health, 2018, 5, e10224.	1.7	8
166	Executive Function Predicts Antidepressant Treatment Noncompletion in Late-Life Depression. Journal of Clinical Psychiatry, $2018, 79, \ldots$	1.1	17
167	Bilateral Repetitive Transcranial Magnetic Stimulation Decreases Suicidal Ideation in Depression. Journal of Clinical Psychiatry, 2018, 79, .	1.1	38
168	Treatment Emergent Suicidal Ideation in depressed older adults. International Journal of Geriatric Psychiatry, 2017, 32, 596-604.	1.3	6
169	Immunological biomarkers associated with brain structure and executive function in lateâ€ife depression: exploratory pilot study. International Journal of Geriatric Psychiatry, 2017, 32, 692-699.	1.3	33
170	Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. American Journal of Psychiatry, 2017, 174, 468-475.	4.0	41
171	Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression. American Journal of Geriatric Psychiatry, 2017, 25, 672-679.	0.6	13
172	Brain-Derived Neurotrophic Factor Expression in Individuals With Schizophrenia and Healthy Aging: Testing the Accelerated Aging Hypothesis of Schizophrenia. Current Psychiatry Reports, 2017, 19, 36.	2.1	41
173	Bone Turnover with Venlafaxine Treatment in Older Adults with Depression. Journal of the American Geriatrics Society, 2017, 65, 2057-2063.	1.3	14
174	Advances in Pharmacotherapy of Late-Life Depression. American Journal of Geriatric Psychiatry, 2017, 25, S7.	0.6	0
175	Pharmacotherapy of Late-Life Mental Disorders: Is There Anything New Under the Sun?. American Journal of Geriatric Psychiatry, 2017, 25, S30-S31.	0.6	0
176	Creation of a Psychosocial Interventions Clinic for Elderly Patients with Schizophrenia. American Journal of Geriatric Psychiatry, 2017, 25, S99.	0.6	0
177	Pharmacotherapy of major depression in late life: what is the role of new agents?. Expert Opinion on Pharmacotherapy, 2017, 18, 599-609.	0.9	21
178	Gray Matter Neuritic Microstructure Deficits in Schizophrenia and Bipolar Disorder. Biological Psychiatry, 2017, 82, 726-736.	0.7	79
179	Extent of Dorsolateral Prefrontal Cortex Plasticity and Its Association With Working Memory in Patients With Alzheimer Disease. JAMA Psychiatry, 2017, 74, 1266.	6.0	118
180	The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis. Psychotherapy and Psychosomatics, 2017, 86, 268-282.	4.0	76

#	Article	IF	CITATIONS
181	311. DLPFC Neuroplasticity and Working Memory Performance in Alzheimer's Disease. Biological Psychiatry, 2017, 81, S128.	0.7	1
182	702. The Behavioural and Neural Correlates of Social Cognition in Youth with Mental Illness. Biological Psychiatry, 2017, 81, S284-S285.	0.7	0
183	Should Benzodiazepines and Anticonvulsants Be Used During Electroconvulsive Therapy?. Journal of ECT, 2017, 33, 237-242.	0.3	16
184	GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. American Journal of Psychiatry, 2017, 174, 1086-1093.	4.0	132
185	Effect of Metabolic Syndrome on Lateâ€Life Depression: Associations with Disease Severity and Treatment Resistance. Journal of the American Geriatrics Society, 2017, 65, 2651-2658.	1.3	27
186	232. Genome-Wide Association Study of Venlafaxine Treatment Remission in Late-Life Depression. Biological Psychiatry, 2017, 81, S95-S96.	0.7	1
187	Changes in Characteristics and Practice Patterns of Ontario Psychiatrists. Canadian Journal of Psychiatry, 2017, 62, 40-47.	0.9	22
188	Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia. American Journal of Geriatric Psychiatry, 2017, 25, 1-10.	0.6	18
189	Gray matter regions statistically mediating the crossâ€sectional association of eotaxin and setâ€shifting among older adults with major depressive disorder. International Journal of Geriatric Psychiatry, 2017, 32, 1226-1232.	1.3	6
190	The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression. Journal of Clinical Psychiatry, 2017, 78, 1149-1154.	1.1	9
191	Anticholinergic Burden and Cognition in Older Patients With Schizophrenia. Journal of Clinical Psychiatry, 2017, 78, e1284-e1290.	1.1	30
192	Unilateral and bilateral MRI-targeted repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled study. Journal of Psychiatry and Neuroscience, 2016, 41, E58-E66.	1.4	76
193	R―and Sâ€citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. British Journal of Clinical Pharmacology, 2016, 82, 784-792.	1.1	54
194	Immunological Markers Associated with Brain Health and Treatment Response in Late-Life Depression: Pilot Study. American Journal of Geriatric Psychiatry, 2016, 24, S106-S107.	0.6	2
195	Subjective Sleep as a Prognostic Factor for Venlafaxine Response in Older Depressed Outpatients. American Journal of Geriatric Psychiatry, 2016, 24, S166.	0.6	0
196	Neuroplasticity Deficits and Working Memory Performance in Individuals with Early Alzheimer's Disease. American Journal of Geriatric Psychiatry, 2016, 24, S112.	0.6	0
197	The Efficacy of Unilateral and Bilateral Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Late-Life Depression. American Journal of Geriatric Psychiatry, 2016, 24, S69-S71.	0.6	1
198	The Association of Baseline Suicidality with Treatment Outcome in Psychotic Depression. American Journal of Geriatric Psychiatry, 2016, 24, S103-S104.	0.6	0

#	Article	IF	CITATIONS
199	Decreased Brain-Derived Neurotrophic Factor in Older Adults with Bipolar Disorder. American Journal of Geriatric Psychiatry, 2016, 24, 596-601.	0.6	23
200	Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation. American Journal of Geriatric Psychiatry, 2016, 24, 918-922.	0.6	11
201	Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology, 2016, 233, 3803-3813.	1.5	11
202	Older Adults' Perspectives on Clinical Research: A Focus Group and Survey Study. American Journal of Geriatric Psychiatry, 2016, 24, 893-902.	0.6	12
203	Beyond integrated care competencies: The imperative for adaptive expertise. General Hospital Psychiatry, 2016, 43, 30-31.	1.2	22
204	An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia. International Journal of Geriatric Psychiatry, 2016, 31, 1116-1123.	1.3	11
205	Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder. Journal of Psychiatric Research, 2016, 81, 112-118.	1.5	30
206	Amyloid deposition in semantic dementia: a positron emission tomography study. International Journal of Geriatric Psychiatry, 2016, 31, 1064-1074.	1.3	9
207	A meta-analysis of the effects of aging on motor cortex neurophysiology assessed by transcranial magnetic stimulation. Clinical Neurophysiology, 2016, 127, 2834-2845.	0.7	117
208	Self-reported obstructive sleep apnea is associated with nonresponse to antidepressant pharmacotherapy in late-life depression. Depression and Anxiety, 2016, 33, 1107-1113.	2.0	15
209	Education's Impact on Healthy Seniors' Attitudes and Health Care Preferences Regarding Different Stages of Alzheimer's Disease. American Journal of Geriatric Psychiatry, 2016, 24, S169-S170.	0.6	0
210	SSRIâ€antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOPâ€PD study. Human Psychopharmacology, 2016, 31, 252-255.	0.7	9
211	Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. American Journal of Psychiatry, 2016, 173, 465-472.	4.0	77
212	Indicators for Remission of Suicidal Ideation Following Magnetic Seizure Therapy in Patients With Treatment-Resistant Depression. JAMA Psychiatry, 2016, 73, 337.	6.0	102
213	The influence of medical burden severity and cognition on functional competence in older community-dwelling individuals with schizophrenia. Schizophrenia Research, 2016, 170, 330-335.	1.1	19
214	Using Evolutionary Theory to Guide Mental Health Research. Canadian Journal of Psychiatry, 2016, 61, 159-165.	0.9	27
215	Prefrontal White Matter Structure Mediates the Influence of GAD1 on Working Memory. Neuropsychopharmacology, 2016, 41, 2224-2231.	2.8	23
216	Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression. JAMA Psychiatry, 2016, 73, 329.	6.0	40

#	Article	IF	CITATIONS
217	Systematic Review of Cognitive Effects of Electroconvulsive Therapy in Late-Life Depression. American Journal of Geriatric Psychiatry, 2016, 24, 547-565.	0.6	52
218	Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS). Journal of Affective Disorders, 2016, 190, 111-114.	2.0	14
219	Trajectories of suicidal ideation in depressed older adults undergoing antidepressant treatment. Journal of Psychiatric Research, 2016, 73, 96-101.	1.5	22
220	Threshold of Dopamine D _{2/3} Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, e1557-e1563.	1.1	11
221	Lifetime History of Depression Predicts Increased Beta-Amyloid Accumulation in Patients with Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2015, 23, S147-S150.	0.6	1
222	Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 49, 743-754.	1.2	33
223	NEUROBIOLOGICAL PREDICTORS OF RESPONSE TO DORSOLATERAL PREFRONTAL CORTEX REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN DEPRESSION: A SYSTEMATIC REVIEW. Depression and Anxiety, 2015, 32, 871-891.	2.0	63
224	Cognitive remediation for older communityâ€dwelling individuals with schizophrenia: a pilot and feasibility study. International Journal of Geriatric Psychiatry, 2015, 30, 1129-1134.	1.3	10
225	Predicting hospital length of stay for geriatric and adult patients with schizophrenia. Journal of Hospital Administration, 2015, 4, 15.	0.0	6
226	The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Clinical Pharmacokinetics, 2015, 54, 1161-1168.	1.6	14
227	Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial. Psychiatric Services, 2015, 66, 1303-1311.	1.1	8
228	Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression. American Journal of Geriatric Psychiatry, 2015, 23, 1270-1275.	0.6	10
229	Small Longitudinal Study of Serum Anticholinergic Activity and Cognitive Change in Community-Dwelling Older Adults. American Journal of Geriatric Psychiatry, 2015, 23, 326-329.	0.6	4
230	Cognitive Remediation for Older Patients with Schizophrenia: A Pilot Study. American Journal of Geriatric Psychiatry, 2015, 23, S72-S73.	0.6	0
231	Lifetime History of Depression Predicts Increased Amyloid- \hat{l}^2 Accumulation in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 45, 907-919.	1.2	49
232	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. Schizophrenia Research, 2015, 161, 429-433.	1.1	22
233	Obstructive Sleep Apnea and Antidepressant Treatment Response in Older Adults. American Journal of Geriatric Psychiatry, 2015, 23, S97-S98.	0.6	0
234	Minimal evidence that untreated psychosis damages brain structures: A systematic review. Schizophrenia Research, 2015, 162, 222-233.	1,1	35

#	Article	IF	CITATIONS
235	Associations of medical comorbidity, psychosis, pain, and capacity with psychiatric hospital length of stay in geriatric inpatients with and without dementia. International Psychogeriatrics, 2015, 27, 313-321.	0.6	14
236	Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia—A [11C]-raclopride PET study. Schizophrenia Research, 2015, 164, 263-267.	1.1	17
237	Superficial white matter as a novel substrate of age-related cognitive decline. Neurobiology of Aging, 2015, 36, 2094-2106.	1.5	65
238	The Relationships Between Vascular Risk, Cognition and Outcome in Late-Life Psychotic Depression. American Journal of Geriatric Psychiatry, 2015, 23, S102-S103.	0.6	0
239	Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. JAMA Psychiatry, 2015, 72, 927.	6.0	77
240	Prediction of Working Memory Performance in Schizophrenia by Plasma Ratio of Clozapine to <i>N</i> -Desmethylclozapine. American Journal of Psychiatry, 2015, 172, 579-585.	4.0	63
241	Hippocampal (subfield) volume and shape in relation to cognitive performance across the adult lifespan. Human Brain Mapping, 2015, 36, 3020-3037.	1.9	101
242	Further Neuroimaging Evidence for the Deficit Subtype of Schizophrenia. JAMA Psychiatry, 2015, 72, 446.	6.0	79
243	Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 386, 2404-2412.	6.3	229
244	The Relationship Between Insight Into Illness and Cognition in Schizophrenia Across the Adult Lifespan. American Journal of Geriatric Psychiatry, 2015, 23, S123.	0.6	0
245	Dopamine D2/3Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. Schizophrenia Bulletin, 2015, 42, sbv106.	2.3	16
246	Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults. JAMA Psychiatry, 2015, 72, 1021.	6.0	54
247	Oxidative Stress in Older Patients with Bipolar Disorder. American Journal of Geriatric Psychiatry, 2015, 23, 314-319.	0.6	34
248	An adaptationist perspective on the etiology of depression. Journal of Affective Disorders, 2015, 172, 315-323.	2.0	108
249	The Impact of Aging, Cognition, and Symptoms on Functional Competence in Individuals With Schizophrenia Across the Lifespan. Schizophrenia Bulletin, 2015, 41, 374-381.	2.3	55
250	Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder. Bipolar Disorders, 2015, 17, 248-256.	1.1	65
251	Disrupted Prefrontal Interhemispheric Structural Coupling in Schizophrenia Related to Working Memory Performance. Schizophrenia Bulletin, 2014, 40, 914-924.	2.3	28
252	Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults. Journal of Clinical Psychiatry, 2014, 75, e785-e793.	1.1	154

#	Article	IF	Citations
253	Methodological Challenges in Determining Longitudinal Associations Between Anticholinergic Drug Use and Incident Cognitive Decline. Journal of the American Geriatrics Society, 2014, 62, 336-341.	1.3	66
254	Social support in late life mania: GERIâ€BD. International Journal of Geriatric Psychiatry, 2014, 29, 1028-1032.	1.3	10
255	The VAGUS insight into psychosis scale – Self-report and clinician-rated versions. Psychiatry Research, 2014, 220, 1084-1089.	1.7	41
256	The VAGUS- Self-Report & Clinician-Rated Versions: A Novel Insight into Psychosis Scale for Use Across the Adult Late-Life Span. American Journal of Geriatric Psychiatry, 2014, 22, S93-S94.	0.6	0
257	Challenges of the Treatment of Neuropsychiatric Symptoms Associated with Dementia. American Journal of Geriatric Psychiatry, 2014, 22, 317-320.	0.6	8
258	Measuring treatment response in psychotic depression: The Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. Journal of Affective Disorders, 2014, 160, 68-73.	2.0	29
259	Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study. Comprehensive Psychiatry, 2014, 55, 1069-1076.	1.5	4
260	Brain Stimulation in the Treatment of Late-Life Severe Mental Illness Other than Unipolar Nonpsychotic Depression. American Journal of Geriatric Psychiatry, 2014, 22, 216-240.	0.6	25
261	Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. World Journal of Biological Psychiatry, 2014, 15, 404-410.	1.3	17
262	Neuroimaging and neurocognitive abnormalities associated with bipolar disorder in old age. International Journal of Geriatric Psychiatry, 2014, 29, 421-427.	1.3	27
263	A Systematic Approach to Pharmacotherapy for Geriatric Major Depression. Clinics in Geriatric Medicine, 2014, 30, 517-534.	1.0	80
264	Depression, Antidepressants, and Bone Health in Older Adults: A Systematic Review. Journal of the American Geriatrics Society, 2014, 62, 1434-1441.	1.3	43
265	Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients with Schizophrenia: A Pilot PET Study. American Journal of Geriatric Psychiatry, 2014, 22, 1007-1016.	0.6	24
266	PIB-Positive PET in Individuals with Early- but Not Late-Onset Frontotemporal Dementia. American Journal of Geriatric Psychiatry, 2014, 22, S81-S82.	0.6	0
267	Developing Physician Consensus on the Reporting of Patients with Mild Cognitive Impairment and Mild Dementia to Transportation Authorities in a Region with Mandatory Reporting Legislation. American Journal of Geriatric Psychiatry, 2014, 22, 1530-1543.	0.6	20
268	Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 83-91.	2.5	15
269	Delusional Depression in Late-Life: Treatment Effects on Mood, Psychosis, Cognition and the Brain. American Journal of Geriatric Psychiatry, 2014, 22, S10.	0.6	О
270	Decrease Brain-Derived Neurotrophic Factor (BDNF) in Older Patients with Bipolar Disorder. American Journal of Geriatric Psychiatry, 2014, 22, S109.	0.6	1

#	Article	IF	CITATIONS
271	Cognitive Remediation for Older Patients with Schizophrenia: A Pilot Study. American Journal of Geriatric Psychiatry, 2014, 22, S91-S92.	0.6	O
272	Dynamic Prediction of Treatment Response in Late-Life Depression. American Journal of Geriatric Psychiatry, 2014, 22, 167-176.	0.6	40
273	Occupancy of Dopamine D3 Receptors by Aripiprazole in Treatment Resistant Late-Life Depressed Patients Depends on Length of Treatment as Evidenced by in vivo Imaging with [11C]-(+)-PHNO. American Journal of Geriatric Psychiatry, 2014, 22, S83-S84.	0.6	4
274	Effect of Sertraline on Risk of Falling in Older Adults with Psychotic Depression on Olanzapine: Results of a Randomized Placebo-Controlled Trial. American Journal of Geriatric Psychiatry, 2014, 22, 332-336.	0.6	13
275	The Role of Untreated Psychosis in Neurodegeneration: A Review of Hypothesized Mechanisms of Neurotoxicity in First-Episode Psychosis. Canadian Journal of Psychiatry, 2014, 59, 513-517.	0.9	34
276	Cognition, Function, and Disability in Patients with Schizophrenia: A Review of Longitudinal Studies. Canadian Journal of Psychiatry, 2014, 59, 13-17.	0.9	111
277	Universal coverage without universal access: a study of psychiatrist supply and practice patterns in Ontario. Open Medicine, 2014, 8, e87-99.	1.5	39
278	Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study. Psychopharmacology, 2013, 228, 43-51.	1.5	15
279	How Can We Improve the Prognosis of Bipolar Disorder in Late Life?. American Journal of Geriatric Psychiatry, 2013, 21, S20.	0.6	1
280	Alterations of Superficial White Matter in Schizophrenia and Relationship to Cognitive Performance. Neuropsychopharmacology, 2013, 38, 1954-1962.	2.8	113
281	Social inequalities in depression and suicidal ideation among older primary care patients. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 59-69.	1.6	35
282	The potential role of dopamine D3 receptor neurotransmission in cognition. European Neuropsychopharmacology, 2013, 23, 799-813.	0.3	153
283	Lack of Insight in Late-Life Schizophrenia: A Function of Illness Severity and Premorbid Intellectual Functioning. American Journal of Geriatric Psychiatry, 2013, 21, S120-S121.	0.6	0
284	Cognitive Performance of Individuals With Schizophrenia Across Seven Decades: AÂStudy Using the MATRICS Consensus Cognitive Battery. American Journal of Geriatric Psychiatry, 2013, 21, 108-118.	0.6	68
285	Genetic variation in the serotonin transporter and serotonin 1B receptor predicts reduced bone formation during serotonin-reuptake inhibitor treatment in older adults. American Journal of Geriatric Psychiatry, 2013, 21, S157-S158.	0.6	0
286	A Comparison of the E-BEHAVE-AD, NBRS, and NPI in Quantifying Clinical Improvement in the Treatment of Agitation and Psychosis Associated With Dementia. American Journal of Geriatric Psychiatry, 2013, 21, 78-87.	0.6	30
287	Insight into illness in late-life schizophrenia: A function of illness severity and premorbid intellectual function. Schizophrenia Research, 2013, 150, 217-222.	1.1	10
288	Cognitive and Functional Ability in Older Adults with Schizophrenia. American Journal of Geriatric Psychiatry, 2013, 21, S119.	0.6	0

#	Article	IF	Citations
289	Neuroimaging Evidence for the Deficit Subtype of Schizophrenia. JAMA Psychiatry, 2013, 70, 472.	6.0	137
290	Does the Redesign of a Psychiatric Inpatient Unit Change the Treatment Process and Outcomes?. Psychiatric Services, 2013, 64, 804-807.	1.1	10
291	PAS-Induced Potentiation of Cortical-Evoked Activity in the Dorsolateral Prefrontal Cortex. Neuropsychopharmacology, 2013, 38, 2545-2552.	2.8	82
292	The Incidence of Tardive Dyskinesia in the Study of Pharmacotherapy for Psychotic Depression. Journal of Clinical Psychopharmacology, 2013, 33, 391-397.	0.7	9
293	Pharmacological Strategies in the Prevention of Relapse After Electroconvulsive Therapy. Journal of ECT, 2013, 29, 3-12.	0.3	66
294	Aging changes and medical complexity in late-life bipolar disorder: emerging research findings that may help advance care. Neuropsychiatry, 2013, 3, 621-633.	0.4	28
295	Canadian Academy of Geriatric Psychiatry Survey of Brief Cognitive Screening Instruments. Canadian Geriatrics Journal, 2013, 16, 54-60.	0.7	26
296	Translocator Protein (18 kDa) Polymorphism (rs6971) Explains <i>in-vivo</i> Brain Binding Affinity of the PET Radioligand [¹⁸ F]-FEPPA. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 968-972.	2.4	131
297	Correlates of Treatment Response in Depressed Older Adults With Bipolar Disorder. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 37-42.	1.2	15
298	Characteristics Associated with Inpatient Versus Outpatient Status in Older Adults with Bipolar Disorder. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 62-68.	1.2	13
299	Predicting Hospital Length of Stay for Geriatric Patients with Mood Disorders. Canadian Journal of Psychiatry, 2012, 57, 627-634.	0.9	1
300	Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Research, 2012, 197, 221-226.	1.7	14
301	Age and Sex Impact Clozapine Plasma Concentrations in Inpatients and Outpatients With Schizophrenia. American Journal of Geriatric Psychiatry, 2012, 20, 53-60.	0.6	44
302	Social Emotion Recognition, Social Functioning, and Attempted Suicide in Late-Life Depression. American Journal of Geriatric Psychiatry, 2012, 20, 257-265.	0.6	140
303	A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World Journal of Biological Psychiatry, 2012, 13, 423-435.	1.3	88
304	Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Research, 2012, 197, 1-6.	1.7	148
305	Age-related decline in white matter tract integrity and cognitive performance: A DTI tractography and structural equation modeling study. Neurobiology of Aging, 2012, 33, 21-34.	1.5	274
306	Cholinergic pathways and cognition in patients with schizophrenia: A pilot study. Schizophrenia Research, 2012, 139, 46-52.	1.1	8

#	Article	IF	CITATIONS
307	Myelin-Associated Glycoprotein Gene and Brain Morphometry in Schizophrenia. Frontiers in Psychiatry, 2012, 3, 40.	1.3	32
308	DISC1 and Striatal Volume: A Potential Risk Phenotype For mental Illness. Frontiers in Psychiatry, 2012, 3, 57.	1.3	13
309	Incorporating temporal features of repeatedly measured covariates into treeâ€structured survival models. Biometrical Journal, 2012, 54, 181-196.	0.6	3
310	Neuroimaging of delusions in Alzheimer's disease. Psychiatry Research - Neuroimaging, 2012, 202, 89-95.	0.9	56
311	Cognition in older adults with bipolar disorder versus major depressive disorder. Bipolar Disorders, 2012, 14, 198-205.	1.1	69
312	Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophrenia Research, 2011, 133, 54-62.	1.1	99
313	Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report. Bipolar Disorders, 2011, 13, 294-302.	1.1	39
314	The ZNF804A Gene: Characterization of a Novel Neural Risk Mechanism for the Major Psychoses. Neuropsychopharmacology, 2011, 36, 1871-1878.	2.8	58
315	Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. Journal of Psychiatric Research, 2011, 45, 896-901.	1.5	17
316	Exploring the effect of inducing long-term potentiation in the human motor cortex on motor learning. Brain Stimulation, 2011, 4, 137-144.	0.7	33
317	Neurobiology of Delusions in Alzheimer's Disease. Current Psychiatry Reports, 2011, 13, 211-218.	2.1	51
318	Use of Lithium in the Treatment of Bipolar Disorder in Late-Life. Current Psychiatry Reports, 2011, 13, 488-492.	2.1	27
319	Depression symptom ratings in geriatric patients with bipolar mania. International Journal of Geriatric Psychiatry, 2011, 26, 1201-1208.	1.3	7
320	Effects of aging on 5â€HT _{2A} R binding: a HRRT PET study with and without partial volume corrections. International Journal of Geriatric Psychiatry, 2011, 26, 1300-1308.	1.3	26
321	Problem-solving therapy reduces disability more than supportive therapy in older adults with major depression and executive dysfunction. Evidence-Based Mental Health, 2011, 14, 77-77.	2.2	1
322	Neurexin-1 and Frontal Lobe White Matter: An Overlapping Intermediate Phenotype for Schizophrenia and Autism Spectrum Disorders. PLoS ONE, 2011, 6, e20982.	1.1	58
323	Acupuncture for the Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, 1129-1135.	1.1	41
324	Clozapine and Global Cognition in Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 431-436.	0.7	35

#	Article	IF	Citations
325	Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. International Clinical Psychopharmacology, 2010, 25, 37-45.	0.9	22
326	Repetitive transcranial magnetic stimulation for refractory symptoms in schizophrenia. Current Opinion in Psychiatry, 2010, 23, 85-90.	3.1	23
327	Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy <i>versus</i> escitalopram with depression care management. International Journal of Geriatric Psychiatry, 2010, 25, 1134-1141.	1.3	43
328	Does age at onset have clinical significance in older adults with bipolar disorder?. International Journal of Geriatric Psychiatry, 2010, 25, 1266-1271.	1.3	15
329	Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERIâ€BD. Bipolar Disorders, 2010, 12, 56-67.	1.1	31
330	The relationship of bipolar disorder lifetime duration and vascular burden to cognition in older adults. Bipolar Disorders, 2010, 12, 851-858.	1.1	29
331	Differentiating the Cognitive Profile of Schizophrenia from That of Alzheimer Disease and Depression in Late Life. PLoS ONE, 2010, 5, e10151.	1.1	29
332	Towards the development of new subtype-specific muscarinic receptor radiopharmaceuticals â€" Radiosynthesis and ex vivo biodistribution of $[\langle \sup 18 \langle \sup F] 3 \cdot (4 \cdot (2 \cdot (2 \cdot (2 \cdot fluoroethoxy)ethoxy)ethylthio) \cdot 1,2,5 \cdot thiadiazol \cdot 3 \cdot yl) \cdot 1 \cdot methyl \cdot 1,2,5,6 \cdot tetrahydrop Canadian Journal of Chemistry, 2010, 88, 1222 \cdot 1232.$	0.6 yridine.	5
333	Diffusion tensor tractography findings in schizophrenia across the adult lifespan. Brain, 2010, 133, 1494-1504.	3.7	131
334	Effect of Age on the Frequency of Anxiety Disorders in Major Depression With Psychotic Features. American Journal of Geriatric Psychiatry, 2010, 18, 404-412.	0.6	35
335	The Role of the Corpus Callosum in Transcranial Magnetic Stimulation Induced Interhemispheric Signal Propagation. Biological Psychiatry, 2010, 68, 825-831.	0.7	114
336	Reducing Suicidal Ideation and Depression in Older Primary Care Patients: 24-Month Outcomes of the PROSPECT Study. American Journal of Psychiatry, 2009, 166, 882-890.	4.0	319
337	Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: A randomized, placebo-controlled study. Psychiatry Research - Neuroimaging, 2009, 171, 1-9.	0.9	15
338	The MMSE is not an adequate screening cognitive instrument in studies of late-life depression. Journal of Psychiatric Research, 2009, 43, 464-470.	1.5	37
339	Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features?. Journal of Affective Disorders, 2009, 112, 250-255.	2.0	7
340	High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late-life depression. Depression and Anxiety, 2009, 26, 266-272.	2.0	29
341	Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. Psychiatry and Clinical Neurosciences, 2009, 63, 244-246.	1.0	20
342	The longitudinal course of cognition in older adults with bipolar disorder. Bipolar Disorders, 2009, 11, 744-752.	1.1	100

#	Article	IF	CITATIONS
343	An improved radiosynthesis of the muscarinic M2 radiopharmaceutical, [18F]FP-TZTP. Applied Radiation and Isotopes, 2009, 67, 611-616.	0.7	20
344	The Mood Disorder Burden Index: A scale for assessing the burden of caregivers to adults with unipolar or bipolar disorder. Psychiatry Research, 2009, 168, 67-77.	1.7	20
345	Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: A survey of 796 outpatients in Japan. Journal of Anxiety Disorders, 2009, 23, 477-481.	1.5	37
346	Long-term stability of measuring D2 receptors in schizophrenia patients treated with antipsychotics. Schizophrenia Research, 2009, 109, 130-133.	1.1	15
347	Developing a Community-Academic Partnership to Improve Recognition and Treatment of Depression in Underserved African American and White Elders. American Journal of Geriatric Psychiatry, 2009, 17, 953-964.	0.6	25
348	Quantitative examination of a novel clustering method using magnetic resonance diffusion tensor tractography. Neurolmage, 2009, 45, 370-376.	2.1	46
349	Sensitivity of Older Patients to Antipsychotic Motor Side Effects: A PET Study Examining Potential Mechanisms. American Journal of Geriatric Psychiatry, 2009, 17, 255-263.	0.6	58
350	Clozapine Exposure and the Impact of Smoking and Gender: A Population Pharmacokinetic Study. Therapeutic Drug Monitoring, 2009, 31, 360-366.	1.0	57
351	D2 Receptor Blockade by Risperidone Correlates With Attention Deficits in Late-Life Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 571-575.	0.7	41
352	A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic Depression. Archives of General Psychiatry, 2009, 66, 838.	13.8	188
353	Empirically Derived Decision Trees for the Treatment of Late-Life Depression. Focus (American) Tj ETQq1 1 0.7843	814.rgBT / 0.4	Oyerlock 10
354	Pilot Study of Augmentation With Aripiprazole for Incomplete Response in Late-Life Depression. Journal of Clinical Psychiatry, 2009, 70, 208-213.	1.1	49
355	Increased Antipsychotic Sensitivity in Elderly Patients. Journal of Clinical Psychiatry, 2009, 70, 397-405.	1.1	104
356	Bipolar Disorder Center for Pennsylvanians: Implementing an Effectiveness Trial to Improve Treatment for At-Risk Patients. Psychiatric Services, 2009, 60, 888-97.	1.1	7
357	Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?. Depression and Anxiety, 2008, 25, 1060-1066.	2.0	97
358	Anticholinergic Activity of 107 Medications Commonly Used by Older Adults. Journal of the American Geriatrics Society, 2008, 56, 1333-1341.	1.3	412
359	Complementary and alternative medicine in the treatment of bipolar disorder $\hat{a} \in \text{``A review of the}$ evidence. Journal of Affective Disorders, 2008, 110, 16-26.	2.0	63
360	Use of Antidepressants in Late-Life Depression. Drugs and Aging, 2008, 25, 841-853.	1.3	38

#	Article	IF	Citations
361	Web-based training and interrater reliability testing for scoring the Hamilton Depression Rating Scale. Psychiatry Research, 2008, 161, 126-130.	1.7	10
362	Effects of Age and Age of Onset on Prescribed Antipsychotic Dose in Schizophrenia Spectrum Disorders: A Survey of 1,418 Patients in Japan. American Journal of Geriatric Psychiatry, 2008, 16, 584-593.	0.6	45
363	Medical Burden in Late-Life Bipolar and Major Depressive Disorders. American Journal of Geriatric Psychiatry, 2008, 16, 194-200.	0.6	78
364	Nature and course of cognitive function in late-life schizophrenia: A systematic review. Schizophrenia Research, 2008, 102, 122-140.	1.1	110
365	An Open-Label Pilot Study of Acetylcholinesterase Inhibitors to Promote Functional Recovery in Elderly Cognitively Impaired Stroke Patients. Cerebrovascular Diseases, 2008, 26, 317-321.	0.8	61
366	Empirically Derived Decision Trees for the Treatment of Late-Life Depression. American Journal of Psychiatry, 2008, 165, 855-862.	4.0	65
367	Twelve-year depressive symptom trajectories and their predictors in a community sample of older adults. International Psychogeriatrics, 2008, 20, 221-36.	0.6	89
368	Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. International Clinical Psychopharmacology, 2008, 23, 130-137.	0.9	15
369	Biomarkers in geriatric psychiatry: searching for the holy grail?. Current Opinion in Psychiatry, 2008, 21, 533-539.	3.1	8
370	Missed Diagnosis of Psychotic Depression at 4 Academic Medical Centers. Journal of Clinical Psychiatry, 2008, 69, 1293-1296.	1.1	68
371	Recovery From Major Depression in Older Adults Receiving Augmentation of Antidepressant Pharmacotherapy. American Journal of Psychiatry, 2007, 164, 892-899.	4.0	97
372	Perception Gap in Quality-of-Life Ratings: An Empirical Investigation of Nursing Home Residents and Caregivers. Gerontologist, The, 2007, 47, 159-168.	2.3	17
373	Relapse During Continuation Pharmacotherapy after Acute Response to ECT: A Comparison of Usual Care versus Protocolized Treatment. Annals of Clinical Psychiatry, 2007, 19, 1-4.	0.6	46
374	Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. British Journal of Psychiatry, 2007, 190, 344-349.	1.7	164
375	Biomarkers in Geriatric Psychiatry. American Journal of Geriatric Psychiatry, 2007, 15, 827-831.	0.6	9
376	Cognitive Impairment in Late-Life Generalized Anxiety Disorder. American Journal of Geriatric Psychiatry, 2007, 15, 673-679.	0.6	164
377	A Double-Blind Comparison of Citalopram and Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Dementia. American Journal of Geriatric Psychiatry, 2007, 15, 942-952.	0.6	225
378	Cognitive Functioning and Instrumental Activities of Daily Living in Late-Life Bipolar Disorder. American Journal of Geriatric Psychiatry, 2007, 15, 174-179.	0.6	88

#	Article	lF	CITATIONS
379	ECT: the preferred treatment for severe depression in late life. International Psychogeriatrics, 2007, 19, 10.	0.6	21
380	Maintenance Treatment for Oldâ€Age Depression Preserves Healthâ€Related Quality of Life: A Randomized, Controlled Trial of Paroxetine and Interpersonal Psychotherapy. Journal of the American Geriatrics Society, 2007, 55, 1325-1332.	1.3	50
381	Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age. Journal of Affective Disorders, 2007, 98, 153-161.	2.0	49
382	Residual symptoms and recurrence during maintenance treatment of late-life depression. Journal of Affective Disorders, 2007, 103, 77-82.	2.0	131
383	Use of OSWALD for analyzing longitudinal data with informative dropout. Computer Methods and Programs in Biomedicine, 2007, 85, 109-114.	2.6	8
384	Statistical analysis of longitudinal psychiatric data with dropouts. Journal of Psychiatric Research, 2007, 41, 1032-1041.	1.5	46
385	Persisting Low Use of Antipsychotics in the Treatment of Major Depressive Disorder With Psychotic Features. Journal of Clinical Psychiatry, 2007, 68, 194-200.	1.1	40
386	Onset of confusion in the context of late-life depression. Journal of Psychiatry and Neuroscience, 2007, 32, 152.	1.4	2
387	Maintenance Treatment of Major Depression in Old Age. New England Journal of Medicine, 2006, 354, 1130-1138.	13.9	408
388	Discrepancies in Information Provided to Primary Care Physicians by Patients With and Without Dementia: The Steel Valley Seniors Survey. American Journal of Geriatric Psychiatry, 2006, 14, 446-455.	0.6	18
389	Ability, Incentives, and Management Feedback: Organizational Change to Reduce Pressure Ulcers in a Nursing Home. Journal of the American Medical Directors Association, 2006, 7, 141-146.	1.2	30
390	Speed of Improvement in Sleep Disturbance and Anxiety Compared With Core Mood Symptoms During Acute Treatment of Depression in Old Age. American Journal of Geriatric Psychiatry, 2006, 14, 550-554.	0.6	26
391	Cardiovascular Changes Associated With Venlafaxine in the Treatment of Late-Life Depression. American Journal of Geriatric Psychiatry, 2006, 14, 796-802.	0.6	100
392	Persistence of Neuropsychologic Deficits in the Remitted State of Late-Life Depression. American Journal of Geriatric Psychiatry, 2006, 14, 419-427.	0.6	240
393	Impact of Prior Treatment Exposure on Response to Antidepressant Treatment in Late Life. American Journal of Geriatric Psychiatry, 2006, 14, 957-965.	0.6	25
394	A Delusion Assessment Scale for Psychotic Major Depression: Reliability, Validity, and Utility. Biological Psychiatry, 2006, 60, 1336-1342.	0.7	35
395	A model of anticholinergic activity of atypical antipsychotic medications. Schizophrenia Research, 2006, 88, 63-72.	1.1	121
396	Pressure Ulcer Prevention in Black and White Nursing Home Residents:. Advances in Skin and Wound Care, 2006, 19, 262-269.	0.5	41

#	Article	IF	CITATIONS
397	What is the Optimal Duration of a Short-term Antidepressant Trial When Treating Geriatric Depression?. Journal of Clinical Psychopharmacology, 2006, 26, 113-120.	0.7	48
398	Elevation in Plasma Abeta42 in Geriatric Depression: A Pilot Study. Neurochemical Research, 2006, 31, 341-349.	1.6	60
399	Preventing depression after stroke. International Review of Psychiatry, 2006, 18, 471-481.	1.4	22
400	Outcomes of Late-Life Anxiety Disorders During 32 Weeks of Citalopram Treatment. Journal of Clinical Psychiatry, 2006, 67, 468-472.	1.1	24
401	Trajectories of Treatment Response in Late-Life Depression. Journal of Clinical Psychopharmacology, 2005, 25, S8-S13.	0.7	57
402	Dr. Lenze and Colleagues Reply. American Journal of Psychiatry, 2005, 162, 2196-2197.	4.0	0
403	Remission in Depressed Geriatric Primary Care Patients: A Report From the PROSPECT Study. American Journal of Psychiatry, 2005, 162, 718-724.	4.0	177
404	Somatic Symptoms in Late-Life Anxiety: Treatment Issues. Journal of Geriatric Psychiatry and Neurology, 2005, 18, 89-96.	1.2	46
405	Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial. American Journal of Psychiatry, 2005, 162, 146-150.	4.0	114
406	Predictors of Adequacy of Depression Management in the Primary Care Setting. Psychiatric Services, 2005, 56, 1524-1528.	1.1	63
407	Review: pharmacotherapy provides minimal improvements in the neuropsychiatric symptoms of dementia. Evidence-Based Mental Health, 2005, 8, 83-83.	2.2	2
408	Organizational Change and Quality Improvement in Nursing Homes: Approaching Success. Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality, 2005, 27, 6-14.	0.3	22
409	Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. American Journal of Geriatric Pharmacotherapy, 2005, 3, 87-91.	3.0	8
410	Generalized anxiety disorder in late life: lifetime course and comorbidity with major depressive disorder. American Journal of Geriatric Psychiatry, 2005, 13, 77-80.	0.6	57
411	The role of medical comorbidity in outcome of major depression in primary care: the PROSPECT study. American Journal of Geriatric Psychiatry, 2005, 13, 861-8.	0.6	49
412	Body pain and treatment response in late-life depression. American Journal of Geriatric Psychiatry, 2005, 13, 188-94.	0.6	32
413	A pilot study of standardized treatment in geriatric bipolar disorder. American Journal of Geriatric Psychiatry, 2005, 13, 319-23.	0.6	28
414	Accelerating symptom-reduction in late-life depression: a double-blind, randomized, placebo-controlled trial of sleep deprivation. American Journal of Geriatric Psychiatry, 2005, 13, 353-8.	0.6	11

#	Article	IF	CITATIONS
415	Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. American Journal of Geriatric Psychiatry, 2005, 13, 535-8.	0.6	29
416	Predictors of Remission After Electroconvulsive Therapy in Unipolar Major Depression. Journal of Clinical Psychiatry, 2005, 66, 1043-1049.	1.1	117
417	Serotonin 1A Receptor Binding and Treatment Response in Late-Life Depression. Neuropsychopharmacology, 2004, 29, 2258-2265.	2.8	170
418	Clinical Outcome of ECT in Patients With Major Depression and Comorbid Borderline Personality Disorder. American Journal of Psychiatry, 2004, 161, 2073-2080.	4.0	93
419	Neuropathologic Correlates of Late-Onset Major Depression. Neuropsychopharmacology, 2004, 29, 2242-2250.	2.8	96
420	Concurrent Psychiatric Diagnoses by Age and Race Among Persons With Bipolar Disorder. Psychiatric Services, 2004, 55, 931-933.	1.1	21
421	Reducing Suicidal Ideation and Depressive Symptoms in Depressed Older Primary Care Patients. JAMA - Journal of the American Medical Association, 2004, 291, 1081.	3.8	855
422	The Nature and Determinants of Neuropsychological Functioning in Late-LifeDepression. Archives of General Psychiatry, 2004, 61, 587.	13.8	521
423	Depression After Stroke: A Prospective Epidemiological Study. Journal of the American Geriatrics Society, 2004, 52, 774-778.	1.3	150
424	Detection and Management of Cognitive Impairment in Primary Care: The Steel Valley Seniors Survey. Journal of the American Geriatrics Society, 2004, 52, 1668-1675.	1.3	119
425	Adverse effects of depression and cognitive impairment on rehabilitation participation and recovery from hip fracture. International Journal of Geriatric Psychiatry, 2004, 19, 472-478.	1.3	185
426	Time Course of Response to Antidepressants in Late-Life Major Depression. Drugs and Aging, 2004, 21, 531-554.	1.3	69
427	Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods. Psychiatry Research, 2004, 129, 209-215.	1.7	56
428	Cognitive Functioning in Late-Life Bipolar Disorder. American Journal of Psychiatry, 2004, 161, 736-738.	4.0	120
429	Actors' Portrayals of Depression to Test Interrater Reliability in Clinical Trials. American Journal of Psychiatry, 2004, 161, 1909-1911.	4.0	16
430	Pharmacotherapy of bipolar disorder in old age: review and recommendations. American Journal of Geriatric Psychiatry, 2004, 12, 342-57.	0.6	43
431	Executive Functioning, Illness Course, and Relapse/Recurrence in Continuation and Maintenance Treatment of Late-Life Depression: Is There a Relationship?. American Journal of Geriatric Psychiatry, 2004, 12, 387-394.	0.6	59
432	Geriatric Depression Treatment in Nonresponders to Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychiatry, 2004, 65, 1634-1641.	1.1	72

#	Article	IF	CITATIONS
433	Correlates of Anticholinergic Activity in Patients With Dementia and Psychosis Treated With Risperidone or Olanzapine. Journal of Clinical Psychiatry, 2004, 65, 1708-1714.	1.1	49
434	Family caregiver functioning in late-life bipolar disorder. American Journal of Geriatric Psychiatry, 2004, 12, 335-6.	0.6	1
435	Good treatment outcomes in late-life depression with comorbid anxiety. Journal of Affective Disorders, 2003, 77, 247-254.	2.0	61
436	Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. Journal of Psychiatric Research, 2003, 37, 99-108.	1.5	252
437	APOE is associated with age-of-onset, but not cognitive functioning, in late-life depression. International Journal of Geriatric Psychiatry, 2003, 18, 1075-1081.	1.3	51
438	•1-Acid Glycoprotein in Late-Life Depression: Relationship to Medical Burden and Genetics. Journal of Geriatric Psychiatry and Neurology, 2003, 16, 235-239.	1.2	7
439	Paroxetine-Induced Hyponatremia in the Elderly due to the Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH). Journal of Geriatric Psychiatry and Neurology, 2003, 16, 160-164.	1.2	24
440	Apathy and Executive Function in Depressed Elderly. Journal of Geriatric Psychiatry and Neurology, 2003, 16, 112-116.	1.2	46
441	Serum Anticholinergic Activity in a Community-Based Sample of Older Adults. Archives of General Psychiatry, 2003, 60, 198.	13.8	262
442	Achieving Long-Term Optimal Outcomes in Geriatric Depression and Anxiety. CNS Spectrums, 2003, 8, 27-34.	0.7	21
443	Educating the families of nursing home residents: a pilot study using a computer-based system. Journal of the American Medical Directors Association, 2003, 4, 128-34.	1.2	11
444	Comparison of Citalopram, Perphenazine, and Placebo for the Acute Treatment of Psychosis and Behavioral Disturbances in Hospitalized, Demented Patients. American Journal of Psychiatry, 2002, 159, 460-465.	4.0	296
445	Risperidone and 9-Hydroxyrisperidone Concentrations Are Not Dependent on Age or Creatinine Clearance among Elderly Subjects. Journal of Geriatric Psychiatry and Neurology, 2002, 15, 77-81.	1.2	7
446	Anxiety Disorders in Late Life: An Evolving Picture. CNS Spectrums, 2002, 7, 805-810.	0.7	3
447	Effect of Nortriptyline and Paroxetine on CYP2D6 Activity in Depressed Elderly Patients. Journal of Clinical Psychopharmacology, 2002, 22, 481-486.	0.7	18
448	Interrater Reliability in Clinical Trials of Depressive Disorders. American Journal of Psychiatry, 2002, 159, 1598-1600.	4.0	41
449	Assessment of Behavioral and Psychological Symptoms of Dementia. CNS Spectrums, 2002, 7, 797-802.	0.7	21
450	The Establishment of a Brain Bank for the Study of Late-life Depression: A Feasibility Study of Factors Facilitating Consent. CNS Spectrums, 2002, 7, 816-821.	0.7	4

#	Article	IF	CITATIONS
451	Clinically Relevant Behaviors in Elderly Hip Fracture Inpatients. International Journal of Psychiatry in Medicine, 2002, 32, 249-259.	0.8	19
452	Assessment of late life depression. Biological Psychiatry, 2002, 52, 164-174.	0.7	137
453	Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biological Psychiatry, 2002, 52, 253-264.	0.7	404
454	Anxiety Symptoms in Elderly Patients with Depression. Drugs and Aging, 2002, 19, 753-760.	1.3	28
455	Identification of Suicidal Ideation and Prevention of Suicidal Behaviour in the Elderly. Drugs and Aging, 2002, 19, 11-24.	1.3	136
456	Primary Care Physicians' Attitude Toward Diagnosis and Treatment of Late-life Depression. CNS Spectrums, 2002, 7, 784-790.	0.7	9
457	Geriatric Psychiatry: Challenges and Opportunities. CNS Spectrums, 2002, 7, 780-780.	0.7	1
458	Course and rate of antidepressant response in the very old. Journal of Affective Disorders, 2002, 69, 177-184.	2.0	51
459	Intent-to-treat analysis for clinical trials: use of data collected after termination of treatment protocol. Journal of Psychiatric Research, 2002, 36, 153-164.	1.5	8
460	Mental health training for nursing home staff using computer-based interactive video: a 6-month randomized trial. Journal of the American Medical Directors Association, 2002, 3, 291-6.	1,2	17
461	Neuroleptic-Induced Parkinsonism in Alzheimer's Disease. Psychiatric Annals, 2002, 32, 249-252.	0.1	4
462	Risk Factors for Falls During Treatment of Late-Life Depression. Journal of Clinical Psychiatry, 2002, 63, 936-941.	1.1	53
463	Effects of nortriptyline and paroxetine on postural sway in depressed elderly patients. American Journal of Geriatric Psychiatry, 2002, 10, 199-205.	0.6	8
464	Cognitive and behavioral correlates of low vitamin B12 levels in elderly patients with progressive dementia. American Journal of Geriatric Psychiatry, 2002, 10, 321-7.	0.6	17
465	Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. American Journal of Geriatric Psychiatry, 2002, 10, 561-7.	0.6	21
466	Response speed and rate of remission in primary and specialty care of elderly patients with depression. American Journal of Geriatric Psychiatry, 2002, 10, 583-91.	0.6	12
467	Verification of scale sub-domains in elderly patients with dementia: a confirmatory factor-analytic approach. American Journal of Geriatric Psychiatry, 2002, 10, 706-14.	0.6	3
468	Endogenous concentrations of DHEA and DHEA-S Decrease with remission of depression in older adults. Biological Psychiatry, 2001, 50, 767-774.	0.7	79

#	Article	lF	CITATIONS
469	Selective Serotonin Reuptake Inhibitors for Late-Life Depression. Drugs and Aging, 2001, 18, 355-368.	1.3	76
470	Dual-task performance in depressed geriatric patients. Psychiatry Research, 2001, 102, 139-151.	1.7	60
471	The 5-HTTPR Polymorphism Confers Liability to a Combined Phenotype of Psychotic and Aggressive Behavior in Alzheimer Disease. International Psychogeriatrics, 2001, 13, 401-409.	0.6	103
472	The 5-HTTPR*S/*L Polymorphism and Aggressive Behavior in Alzheimer Disease. Archives of Neurology, 2001, 58, 1425.	4.9	94
473	Narrowing the Gap in Treatment of Depression. International Journal of Psychiatry in Medicine, 2001, 31, 239-253.	0.8	39
474	Comorbidity of depression and anxiety disorders in later life. Depression and Anxiety, 2001, 14, 86-93.	2.0	143
475	Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. International Journal of Geriatric Psychiatry, 2001, 16, 585-592.	1.3	122
476	Treatment as usual (TAU) control practices in the PROSPECT Study: managing the interaction and tension between research design and ethics. International Journal of Geriatric Psychiatry, 2001, 16, 602-608.	1.3	39
477	The systematic assessment of depressed elderly primary care patients. International Journal of Geriatric Psychiatry, 2001, 16, 560-569.	1.3	39
478	Managing late-life depression in primary care practice: a case study of the Health Specialist's role. International Journal of Geriatric Psychiatry, 2001, 16, 577-584.	1.3	48
479	Subjective health measures and acute treatment outcomes in geriatric depression. International Journal of Geriatric Psychiatry, 2001, 16, 1149-1155.	1.3	37
480	Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depression and Anxiety, 2001, 13, 38-44.	2.0	41
481	Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well. Journal of Affective Disorders, 2001, 65, 155-166.	2.0	39
482	CYP2D6 Genotyping with Oligonucleotide Microarrays and Nortriptyline Concentrations in Geriatric Depression. Neuropsychopharmacology, 2001, 25, 737-743.	2.8	52
483	Continuation Pharmacotherapy in the Prevention of Relapse Following Electroconvulsive Therapy. JAMA - Journal of the American Medical Association, 2001, 285, 1299.	3.8	569
484	Influence of Serotonin-Transporter-Linked Promoter Region Polymorphism on Platelet Activation in Geriatric Depression. American Journal of Psychiatry, 2001, 158, 2074-2076.	4.0	72
485	A Double-Blind Randomized Comparison of Nortriptyline Plus Perphenazine Versus Nortriptyline Plus Placebo in the Treatment of Psychotic Depression in Late Life. Journal of Clinical Psychiatry, 2001, 62, 597-604.	1.1	61
486	Sertraline in the treatment of minor depression in nursing home residents: a pilot study. , 2000, 15, 177-180.		28

#	Article	IF	CITATIONS
487	Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression. Neuropsychopharmacology, 2000, 23, 587-590.	2.8	366
488	Changes in Cognitive Functioning Following Treatment of Late-Life Depression. American Journal of Psychiatry, 2000, 157, 1949-1954.	4.0	319
489	Effect of Paroxetine on Plasma Vasopressin and Water Load Testing in Elderly Individuals. Journal of Geriatric Psychiatry and Neurology, 2000, 13, 212-216.	1.2	11
490	Fluvoxamine Pharmacotherapy of Anxiety Disorders in Later Life: Preliminary Open-Trial Data. Journal of Geriatric Psychiatry and Neurology, 2000, 13, 43-48.	1.2	22
491	The clinical response to total sleep deprivation and recovery sleep in geriatric depression: potential indicators of antidepressant treatment outcome. Psychiatry Research, 2000, 97, 41-49.	1.7	10
492	Pharmacologic Profile of Perphenazine's Metabolites. Journal of Clinical Psychopharmacology, 2000, 20, 181-187.	0.7	26
493	Determinants of Seizure Threshold in ECT: Benzodiazepine Use, Anesthetic Dosage, and Other Factors. Journal of ECT, 2000, 16, 3-18.	0.3	107
494	Bipolar Disorder in the Elderly. Psychiatric Annals, 2000, 30, 473-480.	0.1	32
495	Accelerating Antidepressant Response in Geriatric Depression: A Post Hoc Comparison of Combined Sleep Deprivation and Paroxetine versus Monotherapy with Paroxetine, Nortriptyline, or Placebo. Journal of Geriatric Psychiatry and Neurology, 1999, 12, 67-71.	1.2	11
496	Behavioral Disturbances of Dementia. Journal of Geriatric Psychiatry and Neurology, 1998, 11, 206-212.	1.2	14
497	Treatment-Resistant Depression in Late Life. Journal of Geriatric Psychiatry and Neurology, 1998, 11, 186-193.	1.2	55
498	Is Delirium Different When It Occurs in Dementia?. Journal of Neuropsychiatry and Clinical Neurosciences, 1998, 10, 199-204.	0.9	94
499	Characteristics and Course of Major Depression in Older Primary Care Patients. International Journal of Psychiatry in Medicine, 1998, 28, 421-436.	0.8	77
500	Serum Anticholinergicity in Elderly Depressed Patients Treated With Paroxetine or Nortriptyline. American Journal of Psychiatry, 1998, 155, 1110-1112.	4.0	63
501	Determinants of SPontaneous Extrapyramidal Symptoms in Elderly Psychiatric Inpatients Diagnosed With Alzheimer's Disease, Major Depressive Disorder, or Psychotic Disorders. Journal of Neuropsychiatry and Clinical Neurosciences, 1998, 10, 68-77.	0.9	11
502	Morbidity of Homebound Versus Inpatient Elderly Psychiatric Patients. International Psychogeriatrics, 1998, 10, 117-125.	0.6	11
503	Antidepressant Use Over Time in a Rural Older Adult Population: The MoVIES Project. Journal of the American Geriatrics Society, 1997, 45, 1501-1503.	1.3	27
504	The Relationship Between Selfâ€Rated Health and Depressive Symptoms in an Epidemiological Sample of Communityâ€Dwelling Older Adults. Journal of the American Geriatrics Society, 1997, 45, 954-958.	1.3	184

#	Article	IF	Citations
505	Control-Relevant Intervention in the Treatment of Minor and Major Depression in a Long-Term Care Facility. American Journal of Geriatric Psychiatry, 1997, 5, 247-257.	0.6	35
506	Medical comorbidity in elderly psychiatric inpatients. Biological Psychiatry, 1997, 41, 724-736.	0.7	42
507	Association of Plasma Homovanillic Acid with Behavioral Symptoms in Patients Diagnosed with Dementia: A Preliminary Report. Biological Psychiatry, 1997, 42, 1016-1023.	0.7	20
508	METHODOLOGICAL ISSUES IN CHARACTERIZING TREATMENT RESPONSE IN DEMENTED PATIENTS WITH BEHAVIORAL DISTURBANCES. , 1997, 12, 537-547.		19
509	The Effects of Perphenazine on the Concentration of Nortriptyline and its Hydroxymetabolites in Older Patients. Journal of Clinical Psychopharmacology, 1997, 17, 318-321.	0.7	21
510	Effect of Sertraline on Plasma Nortriptyline Levels in Depressed Elderly. Journal of Clinical Psychiatry, 1997, 58, 440-443.	1.1	43
511	Suicide in Elderly Depressed Patients: Is Active vs. Passive Suicidal Ideation a Clinically Valid Distinction?. American Journal of Geriatric Psychiatry, 1996, 4, 197-207.	0.6	7 5
512	MRI changes in schizophrenia in late life: a preliminary controlled study. Psychiatry Research, 1996, 60, 117-123.	1.7	22
513	Neuroleptic-Induced Parkinsonism in Elderly Patients Diagnosed With Psychotic Major Depression and Dementia of the Alzheimer Type. American Journal of Geriatric Psychiatry, 1996, 4, 311-319.	0.6	10
514	Premorbid History of Major Depression and the Depressive Syndrome of Alzheimer's Disease. American Journal of Geriatric Psychiatry, 1996, 4, 85-90.	0.6	4
515	Effect of continuation treatment on residual symptoms in late-life depression: How well is "well"?. Depression and Anxiety, 1996, 4, 312-319.	2.0	26
516	Comorbid anxiety disorders in late-life depression. Anxiety, 1996, 2, 242-247.	0.5	82
517	Comorbid anxiety disorders in lateâ€life depression. Anxiety, 1996, 2, 242-247.	0.5	3
518	Delusional and Psychotic Depression in Late Life Clinical Research Needs. American Journal of Geriatric Psychiatry, 1996, 4, 77-84.	0.6	3
519	Premorbid History of Major Depression and the Depressive Syndrome of Alzheimerʽs Disease. American Journal of Geriatric Psychiatry, 1996, 4, 85-90.	0.6	11
520	Antipsychotics in Older Patients. Drugs and Aging, 1995, 6, 312-323.	1.3	24
521	Fluoxetine-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Geriatric Case Report and a Review of the Literature. Journal of Geriatric Psychiatry and Neurology, 1994, 7, 254-256.	1.2	19
522	Early Detection of Neuroleptic-Induced Parkinsonism in Elderly Patients with Dementia. Journal of Geriatric Psychiatry and Neurology, 1994, 7, 251-253.	1.2	10

#	Article	IF	CITATIONS
523	A Naturalistic Study of Trazodone in the Treatment of Behavioral Complications of Dementia. American Journal of Geriatric Psychiatry, 1994, 2, 78-85.	0.6	33
524	The Use of the Hamilton Rating Scale for Depression in Elderly Patients With Cognitive Impairment and Physical Illness. American Journal of Geriatric Psychiatry, 1994, 2, 220-229.	0.6	61
525	Depression in late life. Current Opinion in Psychiatry, 1994, 7, 18-21.	3.1	7
526	Neuroleptics in the treatment of psychosis in late life: A rational approach. International Journal of Geriatric Psychiatry, 1993, 8, 979-992.	1.3	21
527	Personality Disorders in Elderly Inpatients With Major Depression. American Journal of Geriatric Psychiatry, 1993, 1, 38-45.	0.6	41
528	Phenomenology and Prevalence of Neuroleptic-Induced Akathisia in Late Life. American Journal of Geriatric Psychiatry, 1993, 1, 136-142.	0.6	8
529	A Study of Elderly Suicide Attempters Admitted to an Inpatient Psychiatric Unit. American Journal of Geriatric Psychiatry, 1993, 1, 126-135.	0.6	9
530	Dyskinesia and Neuroleptic Exposure in Elderly Psychiatric Inpatients. Topics in Geriatrics, 1992, 5, 156-161.	0.9	12
531	Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatry Research, 1992, 41, 237-248.	1.7	1,707
532	A pilot study of interictal cognitive changes in elderly patients during ECT. International Journal of Geriatric Psychiatry, 1992, 7, 407-410.	1.3	11
533	Agitation in Severely Demented Patients. Annals of Clinical Psychiatry, 1992, 4, 207-215.	0.6	14
534	A Prospective Naturalistic Study of Electroconvulsive Therapy in Late-Life Depression. Topics in Geriatrics, 1991, 4, 3-12.	0.9	61